KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Finished Goods (2017 - 2020)

Amneal Pharmaceuticals (AMRX) has 4 years of Finished Goods data on record, last reported at $222.2 million in Q1 2020.

  • For Q1 2020, Finished Goods changed N/A year-over-year to $222.2 million; the TTM value through Mar 2020 reached $222.2 million, changed N/A, while the annual FY2019 figure was $150.7 million, 31.93% down from the prior year.
  • Finished Goods reached $222.2 million in Q1 2020 per AMRX's latest filing, up from $150.7 million in the prior quarter.
  • Across five years, Finished Goods topped out at $250.6 million in Q2 2018 and bottomed at $105.8 million in Q4 2017.
  • Average Finished Goods over 4 years is $193.7 million, with a median of $208.7 million recorded in 2018.
  • Peak YoY movement for Finished Goods: soared 109.19% in 2018, then tumbled 31.93% in 2019.
  • A 4-year view of Finished Goods shows it stood at $105.8 million in 2017, then surged by 109.19% to $221.4 million in 2018, then crashed by 31.93% to $150.7 million in 2019, then skyrocketed by 47.4% to $222.2 million in 2020.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $222.2 million in Q1 2020, $150.7 million in Q4 2019, and $168.2 million in Q3 2019.